C12Y 402/02005
Chondroitin ac lyase
Official title: Chondroitin AC lyase (4.2.2.5)
C12Y402/02005 (Chondroitin ac lyase) appears on 18 US grants and 27 published applications in this corpus.
Search patents in C12Y- Granted patents
- 18
- Published applications
- 27
- Assignees
- 5
- Inventors
- 23
- Latest grant
- 1 May 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 1 | 6 |
| 2010 | 1 | 0 |
| 2011 | 3 | 3 |
| 2012 | 1 | 1 |
| 2013 | 2 | 3 |
| 2014 | 4 | 1 |
| 2015 | 1 | 3 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Compositions and methods for promoting neuronal outgrowth1 May 2018US 9,956,273 B2Acorda Therapeutics, Inc.
- Pharmacological vitreolysis26 Sep 2017US 9,770,494 B2ThromboGenics NV
- Proteoglycan degrading mutants for treatment of CNS27 Dec 2016US 9,528,102 B2Acorda Therapeutics, Inc.
- Compositions and methods for promoting neuronal outgrowth18 Oct 2016US 9,468,671 B2Acorda Therapeutics, Inc.
- Pharmacological vitreolysis17 Nov 2015US 9,186,394 B2ThromboGenics NV
- In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent23 Mar 2023US 2023/0092556 A1Inovio Pharmaceuticals, Inc.
- In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent19 Sep 2019US 2019/0284263 A1Inovio Pharmaceuticals, Inc.
- Fusion proteins for the treatment of cns15 Mar 2018US 2018/0073007 A9Acorda Therapeutics, Inc.
- Proteoglycan degrading mutants for treatment of cns18 May 2017US 2017/0137799 A1Acorda Therapeutics, Inc.
- Compositions and methods for promoting neuronal outgrowth29 Sep 2016US 2016/0279210 A1Acorda Therapeutics, Inc.
Most cited
By later US patents
- Pharmacological vitreolysis11US 7,547,435 B2ThromboGenics NV · 2009
- Pharmacological vitreolysis9US 7,803,368 B2ThromboGenics NV · 2010
- Pharmacological vitreolysis9US 7,867,489 B2ThromboGenics NV · 2011
- Pharmacological vitreolysis9US 7,914,783 B2ThromboGenics NV · 2011
- Pharmacological vitreolysis8US 8,383,105 B2ThromboGenics NV · 2013